PleoPharma Begins Phase 3 Trial of PP-01 for Cannabis Withdrawal Symptoms

PleoPharma Initiates Phase 3 Clinical Trial for Cannabis Withdrawal Treatment

PleoPharma, Inc., a notable clinical-stage company concentrating on health issues related to cannabis, has officially announced the commencement of dosing the first patient in its pivotal Phase 3 clinical trial, designated as CAN-004. This trial is pivotal in evaluating the efficacy of PP-01, an investigational drug specifically targeting cannabis withdrawal symptoms in adults suffering from cannabis use disorder (CUD).

Addressing a Pressing Issue

Cannabis use disorder affects approximately 20.6 million individuals in the United States, highlighting a substantial unmet medical requirement. The initiation of this trial represents a crucial step towards addressing a significant health challenge faced by millions seeking assistance to mitigate their dependency on cannabis. Dr. Ginger Constantine, CEO and co-founder of PleoPharma, emphasized the significance of this action, stating, "Dosing the first patient in our Phase 3 trial is a significant milestone for PleoPharma and an important step forward for patients with cannabis use disorder, who are looking to quit or reduce their cannabis consumption."

Currently, there are no FDA-approved treatments for cannabis withdrawal symptoms, making PP-01 potentially the first medication specifically designed for this purpose. The Fast Track designation received from the U.S. Food and Drug Administration (FDA) further underlines the drug's potential significance in the therapeutic landscape.

Overview of the Trial

The CAN-004 study is structured as a multicenter, randomized, double-blind, placebo-controlled trial to comprehensively assess the safety and effectiveness of PP-01 in adults grappling with moderate to severe CUD. This trial builds upon encouraging results from previous Phase 2b trials and aims to gather data to support a new drug application submission to the FDA for PP-01, which is designed to be taken orally once a day.

Additional details about the trial can be accessed through the ClinicalTrials.gov database under the identifier NCT07644052.

Understanding Cannabis Use Disorder

Cannabis use disorder is a chronic and increasingly common condition. Among the 20.6 million individuals affected in the U.S., over 1.4 million received treatment for CUD in the previous year. The lack of approved medication-assisted treatment underscores the disease's prevalence and the urgent need for effective therapeutic options. Many individuals with CUD experience swift onset of withdrawal symptoms upon cessation or reduction of cannabis use, which often leads to relapse. Common withdrawal symptoms encompass anxiety, irritability, cravings, disturbed sleep, diminished appetite, restlessness, depression, and various physical symptoms.

Targeting the Underlying Mechanisms

PP-01 operates through a dual mechanism of action, addressing both suppressed CB1 receptors and neurotransmitter imbalances in the mesolimbic reward pathway. The drug holds promise as a potential first-in-class treatment aimed at alleviating the withdrawal symptoms faced by many patients struggling with cannabis use disorder. Designed for daily oral administration, PP-01 is intended to act rapidly and is expected to exhibit excellent safety and tolerability profiles.

About PleoPharma

PleoPharma, Inc. is a privately held clinical-stage development enterprise concentrated on addressing addiction medicine and creating solutions for individuals battling cannabis addiction and associated health complications. The company's leadership team is renowned for its extensive experience, including a formidable track record consisting of more than 50 product approvals worldwide and over 100 Investigational New Drug applications (INDs).

For further information regarding PleoPharma, please visit PleoPharma.com. For inquiries related to media coverage, reach out to Brendi Bluitt at [email protected].